Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Clinical Trial Continuity in Asia-Pacific during the COVID-19 pandemic

16 Jun 2020 (Last Updated June 18th, 2020 08:47)

Sponsored by Novotech Sponsored by Visit Company
Clinical Trial Continuity in Asia-Pacific during the COVID-19 pandemic

The leading Asia-Pacific biotech specialist CRO Novotech is releasing a series of webinars about the advantages of conducting clinical trials in the Asia-Pacific. Sites across the APAC region have quickly changed how they manage trials, and most remained able to deliver the clinical trial services their clients need.

Looking at the macro trends of what’s happened over the COVID-19 pandemic period from March through April 2020 there’s been a significant number of clinical trials that have been initiated in Asia Pacific versus North America. During this period, biotech companies have initiated more clinical trials in Asia and Australia/New Zealand than in North America.

Moreover, according to recent research, about 80% of institutions in the US have had a disruption in the ability to enrol new patients to their oncology clinical trials, versus only 40% disruption in the Asia region.

In Australia, there was a national approach led by the prime minister. He formed a national cabinet with our states and territories, and the key decisions came out very quickly. We had rapid border closures having learned from what was going on across Asia. Australia had a very high testing frequency that continues even today even with a low caseload is very low.

New Zealand was a little bit different; they went in a little bit harder. They are a bit stricter with their lockdown measures, as they were very quick about implementing lockdowns. They had about 10 cases reported, when the country went into severe lockdown, in terms of all businesses and schools closing. Again, they have also closed their borders.

In terms of regulatory guidance, Australia was very much governed by the regulations that were released by the FDA, and the EMA. But certainly, we needed our own local regulatory guidance to be followed. It really ended being a collaboration between the Department of Health, all our state and territory health departments, and our National Health and Medical Research Council which came together and released very thorough guidance on how we should approach continuing clinical trials. So, there was a lot of guidance around virtual EC meetings and many ethics committees would continue to meet once a month.


Free Whitepaper

The Trends and Future Trajectory of Biotech Clinical Trials

The COVID-19 pandemic has changed the landscape of clinical trials with innumerable vaccines and therapies racing through trials for market or emergency use approval. Looking forward, these changes are projected to accelerate further with innovation shifting from big pharma to biotechs, leading to a greater need for R&D outsourcing.

Data analyst and business intelligence firm GlobalData has partnered with Novotech, the Asia-Pacific CRO, to compile a white paper that explores some of the trends seen in the past year and outline forecasts for what’s next in the industry. With Asia-Pacific expected to have 24% of the global CRO market by 2024, this white paper also explains why the regions is ideal for outsourcing clinical R&D and how drug development plans help biotechs.

By clicking the “Submit” button above, you accept and acknowledge that your data will be used as described in the Novotech (Australia) Pty Limited Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.